Silence Thera says it is in merger discussions

London, UK-based Silence Therapeutics has revealed that the company is in merger discussions, without naming the potential partner. The company expects the proposed transaction to be treated as a reverse takeover under the AIM Rules.

Accordingly, trading in Silence's shares has been suspended pending publication of an Admission document. The proposed transaction is subject to due diligence and would be conditional upon shareholder approval.

A further announcement will be made in due course, the company said. In August, Silence announced a delivery collaboration agreement with Dainippon Sumitomo Pharma of Japan to demonstrate the functional delivery of Silence's proprietary small interfering RNA molecules to specific targets.